Tibet Pharmaceuticals, Inc. (TBET)

Tibet Pharmaceuticals, Inc. (TBET) — VMCI valuation read

The headline on Tibet Pharmaceuticals, Inc. (TBET) is a 75/100 VMCI score, set against a Healthcare sector median of 50. That 25-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

TBET insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** TBET trades at 25.0x earnings, 39% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 0.8x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on TBET.

TBET fell 2.9% over the trailing 7 days, with a +1.8% read on a 30-day basis.